Novartis Venture Fund Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
10
- Investments
-
324
- Portfolio
-
43
- Exits
-
161
Novartis Venture Fund General Information
Description
Founded in 1996, Novartis Venture Fund is a corporate venture capital arm of Novartis headquartered in Basel, Switzerland. The firm has a regional office in Cambridge, Massachusetts. The firm seeks to invest in the life sciences, oncology, biotechnology, and digital health sectors.
Contact Information
Website
www.nvfund.com
Year Founded
1996
Investor Status
Actively Seeking New Investments
Trade Association
New England Venture Capital Association (NEVCA)
National Venture Capital Association (NVCA)
Primary Investor Type
Corporate Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- Postfach
- 4002 Basel
- Switzerland
+41 061 000 00 00
Novartis Venture Fund Investments (324)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Enterprise Therapeutics | 09-Mar-2022 | Later Stage VC | 00.000 | Drug Discovery | Generating Revenue | 0000 000000000 00 |
| 000000 | 28-Feb-2022 | 000000000000 | 00.000 | Other Healthcare Technology Systems | Clinical Trials - Phase 2 | |
| 000000 000 | 16-Feb-2022 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 0000 0000000 00 |
| 000000000 | 14-Feb-2022 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - Phase 1 | 00000000 00000 00.0 |
| 0000000 000 | 14-Jan-2022 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | 000000 0000000000 |
| 0000000 | 23-Dec-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | 0000000 00000000000000 00.0 |
| 0000000 0000000000 | 23-Nov-2021 | 0000 00000 | 000.00 | Biotechnology | Startup | 0000000 00000000000000 00.0 |
| 000 000000000000 | 04-Oct-2021 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 00000 000000 00.0 |
| Expansion Therapeutics | 29-Sep-2021 | Later Stage VC | 0000 | Drug Discovery | Generating Revenue | 00000 00000 00.0 |
| Immunitas Therapeutics | 18-Aug-2021 | Early Stage VC | 0000 | Drug Discovery | Clinical Trials - General | 00000 00000 00.0 |
Novartis Venture Fund Exits (161)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Viamet Pharmaceuticals Holdings | 10-Jan-2022 | Out of Business | |
| 0000000 000000 | 13-Dec-2021 | 000000000000000000 | 00000 |
| 00000000 000000 | 01-Nov-2021 | 000000000000000000 | 00000 |
| 000000 0000000 | 21-Sep-2021 | 000000000000000000 | |
| 000000000 | 02-Sep-2021 | 0000000 000000 | 000.00 |
| 000000 | 26-Aug-2021 | 000000000000000000 | |
| 00000000 000000000 | 26-Aug-2021 | 0000000 000000 | 00000 |
| 0000000 | 01-Aug-2021 | 0000000000: 000000 | |
| Genedata | 01-Aug-2021 | Secondary Transaction - Private | |
| Rani Therapeutics | 30-Jul-2021 | IPO | 000.00 |
Novartis Venture Fund Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Novartis Venture Fund Team (28)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Anja König Ph.D | Global Head | 00 | 0 | 0 | Basel, Switzerland |
| Bart Dzikowski JD | Managing Director and Head of Transactions & Legal | 0 | 0 | 0 | Basel, Switzerland |
| Aaron Nelson Ph.D | Managing Director | 0 | 0 | 0 | Cambridge, MA |
| Beat Steffen MD | Managing Director | 0 | 0 | 0 | Basel, Switzerland |
| Florian Muellershausen Ph.D | Managing Director | 0 | 0 | Basel, Switzerland |
Novartis Venture Fund Co-Investors (195)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Forbion | 5 | 0 | 0 |
|
|
| Johnson & Johnson Innovation - JJDC | 0 | 0 | 0 |
|
|
| M Ventures | 0 | 0 | 0 |
|
|
| Novo Holdings | 0 | 0 | 0 |
|
|
| OrbiMed | 0 | 0 | 0 |
|
|